Medmix : Fire side chat from the UBS Swiss Equity Technology and Innovation Days on 14 Nov 2023

medmix technology

Dominik Vonier

Head of Drug Delivery

14 November 2023

Providing innovative solutions to help people

live healthier and more confident lives

Disclaimer and other important notes

This presentation contains forward-looking statements that are based on management's current assumptions and expectations concerning future developments, including but not limited to, projections of financial developments, market activities or future performance of products and solutions, which therefore contain certain risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results or performance to differ materially from the statements made in this presentation. These risks and other factors include, among others, general economic and geopolitical conditions, foreign exchange fluctuations, competitive product and pricing pressures, the effect of a pandemic or epidemic, a cyber event, a natural disaster or other force majeure, as well as regulatory developments and changes in tax regimes.

Alternative Performance Measures (APM)

All bridges from reported figures to APM can be found in the financial review of medmix' half-year report 2023 and all definitions of APM can be found in the APM section of medmix' annual report 2022.

2

medmix CONFIDENTIAL

medmix

Our aspiration, mission and vision

ASPIRATION

Be the global leader in high precision delivery devices for the healthcare, consumer & industrial end markets

MISSION

Provide innovative solutions to help millions of people live a healthier and more confident life

VISION

Deliver innovative, reliable and sustainable application solutions that contribute to a better world

medmix CONFIDENTIAL

medmix Key figures		Global
Our key figures
	footprint
~2,600		14
production, logistics
	& distribution
employees		sites
22%
477m
CHF
revenues in 2022	adj. EBITDA	~2.5bn
~900	margin in 2022	products per year

active patents

4

medmix CONFIDENTIAL

medmix Business Structure

Our segments

HEALTHCARE				CONSUMER AND INDUSTRIAL

DRUG DELIVERY

SURGERY

DENTAL

INDUSTRY

BEAUTY

Award-winning,	Pioneer in bone cement	Gold standard in	Leading in industrial	Leading microbrush
proprietary injection	mixing devices	dental mixing	mixing and dispensing	specialist
pen platform		devices	device systems
				5

medmix CONFIDENTIAL

Drug Delivery - Overview

Haselmeier, a medmix brand

• Strong growth since acquisition in 2020 - re-positioning towards higher volumes
• Expanding product portfolio and ramping-up production capabilities
• Establish Haselmeier as preferred partner for our customers and their patients
• New autoinjector platform PiccoJect™ with distinct competitive advantages
• D-Flex™disposable pen, low investment, quick to market
• Portfolio ready for strong growth in obesity, growth disorders, biologics and biosimilars

6

medmix CONFIDENTIAL

Haselmeier Strategy: Complete and flexible offering

For our customers and their patients

Become the preferred partner for pen and autoinjector solutions

• Be the preferred partner for all complex solutions: nothing too complex or too small

• Focus on impactful and high-value indications, eg obesity, growth disorders, auto-immune

Leading specialist for highly customized solutions based on our technology platforms

• We offer a complete portfolio for both standard and flexible solutions

• We are the only full-service provider with locations in EU, US and India

7

medmix CONFIDENTIAL

Haselmeier Portfolio: Products and services

We cover all needs for our customers and their patients

Injection Pens

Autoinjectors

Digital Solutions

Services

Customization:

Design & Development

Regulatory Affairs &

Quality Support

Final Assembly &

Packaging

8

medmix CONFIDENTIAL

Platforms tailored to customer and patients' needs

		Product Platforms				Technology Platforms
	•	Lower capital expenditure			•	Flexible customization options
	•	Lower development costs			•	Flexible financial models
	• Faster time to market			• More flexible in regional sourcing

9

medmix CONFIDENTIAL

Focus on PiccoJect™ autoinjector

Why an autoinjector?

• Simplifies at-home injection
• Ready to use
• Patient ease-of-use
• Safe
• Exact dosing
• Ideal for GLP-1 and biologics

10

medmix CONFIDENTIAL